share_log

Evelo Biosciences | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

Evelo Biosciences | 15-12G:终止注册

美股sec公告 ·  01/26 17:36
Moomoo AI 已提取核心信息
Evelo Biosciences, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934, as well as to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The filing indicates that Evelo Biosciences will no longer be required to file periodic financial reports with the SEC. The decision to deregister was made under Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. The company reported approximately 36 holders of record as of the notice date. The certification was signed by Craig R. Jalbert, the Chief Executive Officer, President, and Director of Evelo Biosciences, on January 26, 2024.
Evelo Biosciences, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934, as well as to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The filing indicates that Evelo Biosciences will no longer be required to file periodic financial reports with the SEC. The decision to deregister was made under Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. The company reported approximately 36 holders of record as of the notice date. The certification was signed by Craig R. Jalbert, the Chief Executive Officer, President, and Director of Evelo Biosciences, on January 26, 2024.
Evelo Biosciences, Inc.已正式向美国证券交易委员会(SEC)提交了15号表格,要求终止其根据1934年《证券交易法》第12(g)条的注册,并暂停其根据该法第13和15(d)条提交报告的义务。该文件表明,Evelo Biosciences将不再需要向美国证券交易委员会提交定期财务报告。取消注册的决定是根据第12g-4(a)(1)条和第15d-6条做出的,如表格上所示。截至通知之日,该公司报告了约36名登记持有人。该认证由Evelo Biosciences首席执行官、总裁兼董事克雷格·贾尔伯特于2024年1月26日签署。
Evelo Biosciences, Inc.已正式向美国证券交易委员会(SEC)提交了15号表格,要求终止其根据1934年《证券交易法》第12(g)条的注册,并暂停其根据该法第13和15(d)条提交报告的义务。该文件表明,Evelo Biosciences将不再需要向美国证券交易委员会提交定期财务报告。取消注册的决定是根据第12g-4(a)(1)条和第15d-6条做出的,如表格上所示。截至通知之日,该公司报告了约36名登记持有人。该认证由Evelo Biosciences首席执行官、总裁兼董事克雷格·贾尔伯特于2024年1月26日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息